Agomab Therapeutics Advances Two Lead Candidates to Phase 2, Extends Cash Runway to H1 2029

summarizeSummary

Agomab Therapeutics NV reported its full year 2025 financial results, confirming a strong cash position and extending its cash runway into the first half of 2029 following a recent IPO. The company also announced positive Phase 2a results for ontunisertib and positive interim Phase 1 results for AGMB-447, both advancing to Phase 2 trials, while pausing development of preclinical asset AGMB-101.

check_boxKey Events

• Strong Cash Position & Extended Runway

  Agomab Therapeutics reported cash, cash equivalents, and investments of €116.5 million as of December 31, 2025. Following net IPO proceeds of $188 million in February/March 2026, the company projects its cash runway will extend into the first half of 2029.

• Ontunisertib (FSCD) Phase 2a Success

  The lead candidate, ontunisertib, achieved its primary safety and tolerability endpoint in the STENOVA Phase 2a trial for Fibrostenosing Crohn's Disease (FSCD). Positive signals were observed on exploratory efficacy endpoints (SES-CD, MRE), and the company is preparing to initiate a Phase 2b trial in H2 2026.

• AGMB-447 (IPF) Phase 1 Progress

  The second clinical-stage candidate, AGMB-447, showed positive interim Phase 1 results in healthy participants for Idiopathic Pulmonary Fibrosis (IPF). Initial tolerability issues were mitigated, and the company is on track to initiate a Phase 2 proof-of-concept study in H2 2026.

• AGMB-101 Development Paused

  Agomab Therapeutics has decided to pause further development of its preclinical asset AGMB-101 (for liver cirrhosis) to explore strategic options, indicating a shift in focus to other therapeutic areas.

auto_awesomeAnalysis

This annual report highlights significant clinical advancements for Agomab Therapeutics' lead product candidates, ontunisertib and AGMB-447, both progressing to Phase 2 trials with positive safety and initial efficacy signals. The successful completion of a recent IPO has also substantially strengthened the company's financial position, providing a cash runway into the first half of 2029, which is critical for a clinical-stage biotech. While the decision to pause development of AGMB-101 is a setback for that specific preclinical asset, it reflects a strategic focus on more advanced programs. The disclosed material weaknesses in internal controls are a concern, but the company has initiated a remediation plan, which investors will monitor for effective implementation. Overall, the clinical pipeline momentum and extended financial stability are key positive takeaways for investors.